The efficacy of levofloxacin-based triple therapy for first-line Helicobacter pylori eradication

Objective & Hypothesis:Objectives: Standard triple therapy composed of a proton pump inhibitor, clarithromycin and amoxicillin has been widely preferred for H. pylori eradication in Turkey and World.

📊

Key Findings & Data:Alternative therapies are currently under investigation because of an increase in clarithromycin resistance.

💡

Conclusion & Impact:The new treatment modalities should be investigated.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Helikobakter pilori · levofloksasin · ilk basamak tedavi.

Abstract

Objectives: Standard triple therapy composed of a proton pump inhibitor, clarithromycin and amoxicillin has been widely preferred for H. pylori eradication in Turkey and World. Alternative therapies are currently under investigation because of an increase in clarithromycin resistance. The aim of this study was to evaluate the efficacy of a levoflox-acin-containing triple therapy. Materials and methods: The study was carried out in 81 H. pylori-infected patients (52 female, 29 male) with nonul-cer dyspepsia. The mean age was found 46.3 ± 13.9. Treatment was indicated with lansoprazol 30 mg b.d., amoxicil-lin 1 g b.d., and levofloxacin 500 mg daily for 7 days. H. pylori status was rechecked by (14)C urea breath test 6-8 weeks after the end of therapy. Results: Totally 81 patients could complete the treatment and follow-up protocol. Effectiveness was 68%. The distrib-tions of age, gender and smoking were similar between eradicated and non-eradicated groups (p > 0.05). Conclusion: Seven-day levofloxacin based triple therapy is not very effective in the first-line treatment of H. pylori in-fection. The new treatment modalities should be investigated.

Özet

Amaç: İlk basamak H.pilori eradikasyonunda Türkiye\'de ve Dünya\'da en çok tercih edilen tedavi protokolü proton pompa inhibitörü, klaritromisin ve amoksisilin içeren standart tedavi rejimidir. Ancak artan klaritromisin direnci sebe-biyle alternatif tedavi rejimleri araştırılmaktadır. Çalışmamızda standart üçlü tedavi rejimindeki klaritromisin yerine le-vofloksasin getirilmesiyle oluşturulan kombinasyonun etkinliğini araştırdık. Gereç ve yöntem: Çalışma, H.pilori ile enfekte 52 kadın, 29 erkek, toplam 81 nonülser dispepsi hastasında tamam-landı (yaş ortalaması 46,3 ± 13,9). Tedavide âlansoprazol 30mg 2x1, levofloksasin 500 mg 1x1, amoksisilin 1 gr 2x1â 7 gün verildi. Tedavi bitiminden 6-8 hafta sonra C14 üre-nefes testiyle tedavinin etkinliği kontrol edildi. Bulgular: Hastaların % 68\'inde H.pilori negatifliği sağlandı. Eradikasyon sağlanan ve sağlanmayan hasta grupları yaş, sigara ve cinsiyet dağılımı yönünden benzer bulundu (p > 0,05). Sonuç: İlk basamak H.pilori eradikasyonunda 7 gün süreyle verilen levofloksasin temelli üçlü tedavi yeterince etkin değildir. Yeni tedavi protokollerine ihtiyaç duyulmaktadır.

Keywords

Helikobakter pilori levofloksasin ilk basamak tedavi.Levofloxacin Helicobacter pylori first-line therapy.

🔖

Cite This Article

AYDIN, Y., NAZLIGÜL, Y., YENİOVA, A. Ö., KEFELİ, A., ŞİMŞEK, G., SAÇIKARA, M., AKKUŞ, İ. H. (2011). The efficacy of levofloxacin-based triple therapy for first-line Helicobacter pylori eradication. Dicle Tıp Dergisi, Cilt: 38 - Sayı: 2, 197–201. https://ajindex.com/articles/485457

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000;22(3):283-97.
Makola Di Peura DA, Crowe SE. Helicobacter pylori infec- tion and related gastrointestinal diseases. J Clin Gastroen- terol 2007;41(4):548-58.
Tomita T, Fukuda Y, Tamura K, et al. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer dis- ease. Aliment Pharmacol Ther 2002;16 (Suppl 2):204-9.
Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication thera- py in patients with peptic ulcer diseases. J Gastroenterol 2007;42 (Suppl 17):21-7.
Zullo A, Hassan C, Cristofari F, Perri F, Morini S. Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond. World J Gastrointest On- col 2010;2(2):181-6.
Ağbaba E, Nazlıgül Y, Yeniova AÖ, ve ark. Helikobakter pilo- ri eradikasyonunun fonksiyonel dispepsi semptomları üze- rine kısa dönem etkileri. Dicle Tıp Derg 2010;37(2):211-6.
Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication tre- atment for non-ulcer dyspepsia. Dyspepsia Review Group BMJ 2000;16;321(5):659-64.
Malfertheiner P, Megraud F, O’Morain C, et al. Current con- cepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56(6):772- 81. Fock KM. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24(11):1587-600.
Göral V, Zeyrek FY, Gül K. Helikobakter pilori enfeksiyo- nunda antibiyotik direnci. Türkiye Klin Gastroenterohepa- tol Derg 2000;11(1):87-92.
Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheyk- holeslami A. Increase in resistance rates of H. pylori iso- lates to metronidazole and tetracycline--comparison of three 3-year studies. Arch Iran Med 2010;13(2):177-87.
Agudo S, Alarcón T, Cibrelus L, Urruzuno P, Martínez MJ, López-Brea M. [High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical iso- lates obtained from Spanish children]. Rev Esp Quimioter 2009;22(1):88-92.
Masuda H, Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Characteristics and trends of clarithromycin- resistant Helicobacter pylori isolates in Japan over a de- cade. Pathobiology 2004;71(2):159-63.
Sasaki M, Ogasawara N, Utsumi K, et al. Changes in 12- year first-line eradication rate of Helicobacter pylor